Li Z, Zhuang X, Pan C-H, Yan Y, Thummalapalli R, Hallin J, Torborg S, Singhal A, Chang JC, Manchado E et al..  2024.  Alveolar Differentiation Drives Resistance to KRAS Inhibition in Lung Adenocarcinoma.. Cancer Discov. 14(2):308-325.

Goncalves MD, Taylor S, Halpenny DF, Schwitzer E, Gandelman S, Jackson J, Lukose A, Plodkowski AJ, Tan KS, Dunphy M et al..  2018.  Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer.. Clin Radiol. 73(5):505.e1-505.e8.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, S Kang P, Shankaran V et al..  2017.  IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.. J Clin Invest. 127(8):2930-2940.

Xue Y, Lito P.  2017.  Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.. Clin Cancer Res. 23(6):1365-1367.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM et al..  2016.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.. Nat Med. 22(12):1402-1410.

Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK, Mittal V, Somwar R, Stiles BM, Du Y-CNancy.  2016.  Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma.. Oncotarget. 7(26):39957-39969.

Ross JB, Huh D, Noble LB, Tavazoie SF.  2015.  Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.. Nat Cell Biol. 17(5):651-64.

Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S et al..  2013.  Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma.. Mol Cell. 50(2):185-99.

Wei H-J, Wu ATH, Hsu C-H, Lin Y-P, Cheng W-F, Su C-H, Chiu W-T, Whang-Peng J, Douglas FL, Deng W-P.  2011.  The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.. Mol Ther. 19(12):2249-57.

Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB.  2009.  Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells.. J Clin Invest. 119(7):2042-51.

Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.  2002.  Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.. Oncogene. 21(1):108-18.

Pomerantz AH, Derasari MD, Sethi SS, Khan S.  1988.  Early post-pneumonectomy bronchial stump fistula.. Chest. 93(3):654-7.